-
Mashup Score: 0Prevalence and Correlates of Co-Occurring Allergies in a US Food Allergy Patient Registry - 2 year(s) ago
Article InfoPublication HistoryAccepted: October 6, 2022Received in revised form: August 26, 2022Received: June 20, 2022Publication stageIn Press Journal Pre-ProofFootnotesClinical Implications: Our study indicates that clinicians treating individuals with common primary allergies consider sociodemographic risk factors when…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 2RNA-Based Therapy For Dravet Syndrome - 2 year(s) ago
As Dr. Barbier of CAMP4 Therapeutics explains, CMP-SCN is an investigational RNA-based therapy designed to directly upregulate gene expression of SCN1A
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ann Barbier, MD, PhD, Chief Medical Officer at CAMP4 Therapeutics, discusses CAMP4’s investigational RNA-based therapy for Dravet syndrome, CMP-SCN #CO-3527 @camp4tx @DravetUK @curedravet @DSFeu @dravetCanada @FundacionDravet https://t.co/xxsHWFYPie
-
-
Mashup Score: 1RNA-Based Therapy For Dravet Syndrome - 2 year(s) ago
As Dr. Barbier of CAMP4 Therapeutics explains, CMP-SCN is an investigational RNA-based therapy designed to directly upregulate gene expression of SCN1A
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ann Barbier, MD, PhD, Chief Medical Officer at CAMP4 Therapeutics, discusses CAMP4’s investigational RNA-based therapy for Dravet syndrome, CMP-SCN #CO-3527 @camp4tx @DravetUK @curedravet @DSFeu @dravetCanada @FundacionDravet https://t.co/xxsHWGfSke
-
-
Mashup Score: 0RNA-Based Therapy For Dravet Syndrome - 2 year(s) ago
As Dr. Barbier of CAMP4 Therapeutics explains, CMP-SCN is an investigational RNA-based therapy designed to directly upregulate gene expression of SCN1A
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ann Barbier, MD, PhD, Chief Medical Officer at CAMP4 Therapeutics, discusses CAMP4’s investigational RNA-based therapy for Dravet syndrome, CMP-SCN #CO-3527 @camp4tx @DravetUK @curedravet @DSFeu @dravetCanada @FundacionDravet https://t.co/xxsHWFYhsG
-
-
Mashup Score: 0RNA-Based Therapy For Dravet Syndrome - 2 year(s) ago
As Dr. Barbier of CAMP4 Therapeutics explains, CMP-SCN is an investigational RNA-based therapy designed to directly upregulate gene expression of SCN1A
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ann Barbier, MD, PhD, Chief Medical Officer at CAMP4 Therapeutics, discusses CAMP4’s investigational RNA-based therapy for Dravet syndrome, CMP-SCN #CO-3527 @camp4tx @DravetUK @curedravet @DSFeu @dravetCanada @FundacionDravet https://t.co/xxsHWFYhsG
-
-
Mashup Score: 2RNA-Based Therapy For Dravet Syndrome - 2 year(s) ago
As Dr. Barbier of CAMP4 Therapeutics explains, CMP-SCN is an investigational RNA-based therapy designed to directly upregulate gene expression of SCN1A
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ann Barbier, MD, PhD, Chief Medical Officer at CAMP4 Therapeutics, discusses CAMP4’s investigational RNA-based therapy for Dravet syndrome, CMP-SCN #CO-3527 @camp4tx @DravetUK @curedravet @DSFeu @dravetCanada @FundacionDravet https://t.co/xxsHWFYhsG
-
-
Mashup Score: 2A Major Win in the Courts for Colorado’s Paid Family and Medical Leave Law - A Better Balance - 2 year(s) ago
In a historic victory for hardworking Coloradans and small businesses across the state of Colorado, the Colorado Supreme Court – the highest court in the state – unanimously upheld the state’s paid family and medical leave law, paving the way for its continued implementation and a successful launch of benefits in 2024.
Source: A Better BalanceCategories: Latest Headlines, PediatricsTweet-
Way to go #CO! Last week, Colorado’s Supreme Court upheld the state’s #PaidLeave law, opening the door for families across the state to get the leave they need. Read more about the decision, here: https://t.co/SEeaYELFx6 @ColoradoKidsOrg @ClaytonLearning
-
-
Mashup Score: 0RNA-Based Therapy For Dravet Syndrome - 2 year(s) ago
As Dr. Barbier of CAMP4 Therapeutics explains, CMP-SCN is an investigational RNA-based therapy designed to directly upregulate gene expression of SCN1A
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ann Barbier, MD, PhD, Chief Medical Officer at CAMP4 Therapeutics, discusses CAMP4’s investigational RNA-based therapy for Dravet syndrome, CMP-SCN #CO-3527 @camp4tx @DravetUK @curedravet @DSFeu @dravetCanada @FundacionDravet https://t.co/xxsHWFYhsG
-
-
Mashup Score: 2Risk factors for changes in carotid intima media thickness and plaque over 5 years in women with systemic lupus erythematosus - 2 year(s) ago
Objective To investigate the occurrence of and risk factors for progression of carotid intima media thickness (IMT) and plaque in women with and without SLE. Methods A cohort of 149 women with SLE and 126 controls participated in SOLVABLE (Study of Lupus Vascular and Bone Long-term Endpoints). Demographics, cardiovascular and SLE factors, and laboratory assessments were collected at baseline….
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
This week on LSM: Study shows that higher #fasting #glucose and lower #fibrinogen level were #riskfactors for #progression of intima media thickness over a span of 5 years in adult #women with #lupus. #SLE #autoimmunity #Co-morbidities #Cardiovascular https://t.co/RtDGWp6cMN
-
-
Mashup Score: 0Risk factors for changes in carotid intima media thickness and plaque over 5 years in women with systemic lupus erythematosus - 2 year(s) ago
Objective To investigate the occurrence of and risk factors for progression of carotid intima media thickness (IMT) and plaque in women with and without SLE. Methods A cohort of 149 women with SLE and 126 controls participated in SOLVABLE (Study of Lupus Vascular and Bone Long-term Endpoints). Demographics, cardiovascular and SLE factors, and laboratory assessments were collected at baseline….
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
This week on LSM: Study shows that higher #fasting #glucose and lower #fibrinogen level were #riskfactors for #progression of intima media thickness over a span of 5 years in adult #women with #lupus. #SLE #autoimmunity #Co-morbidities #Cardiovascular https://t.co/RtDGWp6cMN
-
In Press! #Prevalence and #Correlates of #Co- #Occurring #Allergies in a #US #Food #Allergy #Patient #Registry https://t.co/ZOWo3hnJ3a